Protalix BioTherapeutics 3/14/2024 Earnings Report

Protalix BioTherapeutics EPS Results

• Actual EPS: -$0.07
• Consensus EPS: -$0.03
• Beat/Miss: Missed by -$0.04
• One Year Ago EPS: N/A

Protalix BioTherapeutics Revenue Results

• Actual Revenue: $10.49 million
• Expected Revenue: $8.15 million
• Beat/Miss: Beat by +$2.34 million
• YoY Revenue Growth: N/A

Protalix BioTherapeutics Announcement Details

• Date: 3/14/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Protalix BioTherapeutics (NYSE:PLX) (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S. Food and Drug Administration in 2012 for the treatment of Gaucher disease, marking a milestone as the first plant cell–expressed therapeutic to reach the market. In addition to its marketed product, Protalix maintains a robust pipeline that includes pegunigalsidase alfa for Fabry disease and an oral anti‐TNF fusion protein candidate for inflammatory bowel disease. These programs reflect the company’s strategic emphasis on orphan and specialty indications where innovative biologics can offer differentiated therapeutic value.

Since its founding in the early 1990s, Protalix has established partnerships and licensing agreements with leading pharmaceutical companies, broadening the global reach of its products and pipeline candidates. Collaborations with industry partners such as Pfizer have facilitated the commercial launch of ELELYSO in key markets across North America, Europe and Latin America. The company continues to explore strategic licensing opportunities to maximize the clinical and commercial potential of its proprietary proteins.

Protalix is led by a management team and board of directors with deep expertise in biotechnology development, regulatory affairs and commercial operations. The company’s strategy centers on advancing its pipeline through clinical development, securing regulatory approvals and forging partnerships to address unmet medical needs in rare and specialty disease markets. By combining its unique plant‐based manufacturing platform with a focus on high‐value therapeutic areas, Protalix aims to deliver innovative treatments while maintaining operational efficiency and scalability.